Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

about

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

Item

http://www.wikidata.org/entity/Q57492447

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@en

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@nl

type

Item

label

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@en

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@nl

prefLabel

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@en

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@nl

P1476

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

@en

P2093

Alessia Cimadamore

http://www.w3.org/2001/XMLSchema#string

Antonio Lopez-Beltran

http://www.w3.org/2001/XMLSchema#string

Francesco Massari

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Lidia Gatto

http://www.w3.org/2001/XMLSchema#string

Marina Scarpelli

http://www.w3.org/2001/XMLSchema#string

Matteo Santoni

http://www.w3.org/2001/XMLSchema#string

Vincenzo Di Nunno

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

P304

397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00397

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rodolfo Montironi

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30319966

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6165898

http://www.w3.org/2001/XMLSchema#string